vs

Side-by-side financial comparison of ACV Auctions Inc. (ACVA) and Ascendis Pharma A/S (ASND). Click either name above to swap in a different company.

Ascendis Pharma A/S is the larger business by last-quarter revenue ($267.3M vs $183.6M, roughly 1.5× ACV Auctions Inc.). On growth, Ascendis Pharma A/S posted the faster year-over-year revenue change (42.3% vs 15.1%). Over the past eight quarters, Ascendis Pharma A/S's revenue compounded faster (60.7% CAGR vs 12.3%).

ACV Auctions Inc. operates a leading digital wholesale vehicle auction platform serving automotive dealers across the U.S. and Canada. It offers end-to-end services including transparent vehicle inspections, secure payment processing, and logistics support, enabling efficient trading of used vehicles between registered wholesale buyers and sellers.

Growth hormone therapy refers to the use of growth hormone (GH) as a prescription medication—it is one form of hormone therapy. Growth hormone is a peptide hormone secreted by the pituitary gland that stimulates growth and cell reproduction. In the past, growth hormone was extracted from human pituitary glands. Growth hormone is now produced by recombinant DNA technology and is prescribed for a variety of reasons. GH therapy has been a focus of social and ethical controversies for 50 years.

ACVA vs ASND — Head-to-Head

Bigger by revenue
ASND
ASND
1.5× larger
ASND
$267.3M
$183.6M
ACVA
Growing faster (revenue YoY)
ASND
ASND
+27.2% gap
ASND
42.3%
15.1%
ACVA
Faster 2-yr revenue CAGR
ASND
ASND
Annualised
ASND
60.7%
12.3%
ACVA

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ACVA
ACVA
ASND
ASND
Revenue
$183.6M
$267.3M
Net Profit
Gross Margin
90.5%
Operating Margin
-9.7%
Net Margin
Revenue YoY
15.1%
42.3%
Net Profit YoY
EPS (diluted)
$-0.12

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ACVA
ACVA
ASND
ASND
Q4 25
$183.6M
$267.3M
Q3 25
$199.6M
$230.7M
Q2 25
$193.7M
$170.7M
Q1 25
$182.7M
$109.0M
Q4 24
$159.5M
$187.8M
Q3 24
$171.3M
$62.5M
Q2 24
$160.6M
$38.9M
Q1 24
$145.7M
$103.6M
Net Profit
ACVA
ACVA
ASND
ASND
Q4 25
Q3 25
$-24.5M
$-65.9M
Q2 25
$-7.3M
$-42.0M
Q1 25
$-14.8M
$-102.2M
Q4 24
Q3 24
$-16.0M
$-107.1M
Q2 24
$-17.1M
$-118.1M
Q1 24
$-20.5M
$-141.5M
Gross Margin
ACVA
ACVA
ASND
ASND
Q4 25
90.5%
Q3 25
89.5%
Q2 25
80.1%
Q1 25
82.6%
Q4 24
91.9%
Q3 24
80.6%
Q2 24
68.2%
Q1 24
92.1%
Operating Margin
ACVA
ACVA
ASND
ASND
Q4 25
-9.7%
Q3 25
-11.9%
5.1%
Q2 25
-3.7%
-33.5%
Q1 25
-7.9%
-103.2%
Q4 24
-16.2%
Q3 24
-10.0%
-167.3%
Q2 24
-11.6%
-370.2%
Q1 24
-15.5%
-51.2%
Net Margin
ACVA
ACVA
ASND
ASND
Q4 25
Q3 25
-12.3%
-28.5%
Q2 25
-3.8%
-24.6%
Q1 25
-8.1%
-93.7%
Q4 24
Q3 24
-9.4%
-171.5%
Q2 24
-10.6%
-303.9%
Q1 24
-14.1%
-136.6%
EPS (diluted)
ACVA
ACVA
ASND
ASND
Q4 25
$-0.12
Q3 25
$-0.14
Q2 25
$-0.04
Q1 25
$-0.09
Q4 24
$-0.15
Q3 24
$-0.10
Q2 24
$-0.10
Q1 24
$-0.13

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ACVA
ACVA
ASND
ASND
Cash + ST InvestmentsLiquidity on hand
$271.5M
$665.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$429.7M
$-175.8M
Total Assets
$1.1B
$1.4B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ACVA
ACVA
ASND
ASND
Q4 25
$271.5M
$665.3M
Q3 25
$265.3M
$582.2M
Q2 25
$258.4M
$533.6M
Q1 25
$291.9M
$559.4M
Q4 24
$224.1M
$604.3M
Q3 24
$252.5M
$675.6M
Q2 24
$215.0M
$279.4M
Q1 24
$209.8M
$345.9M
Stockholders' Equity
ACVA
ACVA
ASND
ASND
Q4 25
$429.7M
$-175.8M
Q3 25
$434.4M
$-188.0M
Q2 25
$448.8M
$-202.6M
Q1 25
$439.6M
$-205.0M
Q4 24
$440.0M
$-114.2M
Q3 24
$456.2M
$-105.1M
Q2 24
$457.6M
$-346.8M
Q1 24
$458.3M
$-257.2M
Total Assets
ACVA
ACVA
ASND
ASND
Q4 25
$1.1B
$1.4B
Q3 25
$1.2B
$1.2B
Q2 25
$1.1B
$1.2B
Q1 25
$1.2B
$1.1B
Q4 24
$984.1M
$1.3B
Q3 24
$1.0B
$1.2B
Q2 24
$1.0B
$819.0M
Q1 24
$1.0B
$866.7M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ACVA
ACVA
ASND
ASND
Operating Cash FlowLast quarter
$-12.4M
$58.2M
Free Cash FlowOCF − Capex
$-14.7M
FCF MarginFCF / Revenue
-8.0%
Capex IntensityCapex / Revenue
1.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$69.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ACVA
ACVA
ASND
ASND
Q4 25
$-12.4M
$58.2M
Q3 25
$10.3M
Q2 25
$13.7M
Q1 25
$66.6M
$-15.5M
Q4 24
$-3.2M
$-330.7M
Q3 24
$21.1M
Q2 24
$4.5M
Q1 24
$43.0M
$-109.7M
Free Cash Flow
ACVA
ACVA
ASND
ASND
Q4 25
$-14.7M
Q3 25
$7.7M
Q2 25
$10.9M
Q1 25
$65.3M
Q4 24
$-3.9M
Q3 24
$20.2M
Q2 24
$2.7M
Q1 24
$41.9M
FCF Margin
ACVA
ACVA
ASND
ASND
Q4 25
-8.0%
Q3 25
3.8%
Q2 25
5.6%
Q1 25
35.7%
Q4 24
-2.5%
Q3 24
11.8%
Q2 24
1.7%
Q1 24
28.8%
Capex Intensity
ACVA
ACVA
ASND
ASND
Q4 25
1.2%
Q3 25
1.3%
Q2 25
1.5%
Q1 25
0.7%
Q4 24
0.4%
Q3 24
0.6%
Q2 24
1.1%
Q1 24
0.7%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ACVA
ACVA

Auction Marketplace Revenue$77.6M42%
Other Marketplace Revenue$72.4M39%
Customer Assurance$24.1M13%
Data Services Revenue$9.4M5%

ASND
ASND

Segment breakdown not available.

Related Comparisons